ACOR stock gains after winning $16.5M from Alkermes in arbitration case (NASDAQ:ACOR)
seekingalpha.com
finance
2022-10-17 11:53:56

Zhanna Hapanovich/iStock via Getty Images Acorda Therapeutics (NASDAQ:ACOR), a biotech focused on neurological disorders, announced Sunday that a panel of arbitrators awarded it $16.5M from Alkermes (ALKS) in connection with a licensing dispute between the two over multiple sclerosis therapy Ampyra. ACOR shares added ~46% pre-market on Monday in reaction to the news. The decision comes after ACOR sought the intervention of the American Arbitration Association in July 2020 following a dispute with ALKS with the expiration of an Ampyra patent in 2018.
